Cardiogenesis patents angiogenic growth factors:
This article was originally published in Clinica
Cardiogenesis has been granted a patent covering the use of angiogenic growth factors in the treatment of severe angina resulting from coronary artery disease. The company, which has obtained exclusive licenses to the technology from its co-developers, Indiana University and Columbia University, plans to use the growth factors in conjunction with transmyocardial revascularisation (TMR) technology. Cardiogenesis recently merged with Eclipse Surgical Technologies, whose TMR system has been recommended for approval by an FDA panel (see Clinica No 832, p 15).
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.